Roivant Sciences Ltd. cash flow to debt ratio of -698.40% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Roivant Sciences Ltd.'s free cash flow has increased -10.13% from $-844.05M last year to $-758.56M, signaling increasing performance

Roivant Sciences Ltd.'s debt to equity ratio is 0.03, which means that the company's assets are healthy financed, signaling financial stability.

Roivant Sciences Ltd.'s debt has increased relative to shareholder equity from 0.02 last year to 0.03 today, signaling weakened financials

Roivant Sciences Ltd. has a net cash position, so leverage is healthy.

Roivant Sciences Ltd. earns at least as much interest as it pays. Interest obligations are fully covered.

Roivant Sciences Ltd.'s profit margin has decreased (497.15%) in the last year from -591.96% to -3.53K%, signaling decreasing performance

Roivant Sciences Ltd.'s short-term assets of $5.17B exceed its short-term liabilities of $281.24M

Roivant Sciences Ltd.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Roivant Sciences Ltd.'s return on equity of -6.12%, is lower than 15.00%, indicating bad performance

Roivant Sciences Ltd.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Roivant Sciences Ltd. had positive net income in only 1 out of 5 years, indicating unstable earnings

Roivant Sciences Ltd. has negative free cash flow, indicating the company is burning cash rather than generating it

Roivant Sciences Ltd. has negative free cash flow, indicating cash burn

Roivant Sciences Ltd.'s yearly earnings has decreased 74.30% since last year from $-171.98M to $-299.77M, signaling decreasing performance

Roivant Sciences Ltd.'s yearly revenue has decreased 71.57% since last year from $29.05M to $8.26M, signaling decreasing performance

ROIC -27.20% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Roivant Sciences Ltd.'s 3-year revenue CAGR of -36.01% is negative, indicating declining revenue over the past 3 years

Roivant Sciences Ltd. had revenue growth in only 2 out of 5 years, indicating inconsistent revenue performance

Roivant Sciences Ltd. had positive ROE in only 1 out of 5 years, indicating inconsistent returns on equity

Roivant Sciences Ltd. has insufficient data to evaluate this check.

Roivant Sciences Ltd. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Roivant Sciences Ltd. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Roivant Sciences Ltd. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Roivant Sciences Ltd. has insufficient data to evaluate this check.

Roivant Sciences Ltd. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Roivant Sciences Ltd. has a price-to-book ratio of 5.24x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Roivant Sciences Ltd. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue